Similar articles for PMID: 31643797

Year	Number of Results
2012	1
2016	1
2017	2
2018	9
2019	11
2020	15
2021	21
2022	36
2023	24
2024	2

1

[No authors listed] [No authors listed] 2018 Aug 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Aug 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643797 Free Books & Documents. Review.

2

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.

Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO; AXLES 1 Investigators. Insogna KL, et al. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. J Bone Miner Res. 2018. PMID: 29947083 Free article. Clinical Trial.

3

What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review.

Lafage-Proust MH. Lafage-Proust MH. Ther Adv Rare Dis. 2022 Feb 21;3:26330040221074702. doi: 10.1177/26330040221074702. eCollection 2022 Jan-Dec. Ther Adv Rare Dis. 2022. PMID: 37180412 Free PMC article. Review.

4

The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.

Sugarman J, Maruri A, Hamilton DJ, Tabatabai L, Luca D, Cimms T, Krolczyk S, Roberts MS, Carpenter TO. Sugarman J, et al. Bone. 2023 Jan;166:116598. doi: 10.1016/j.bone.2022.116598. Epub 2022 Oct 27. Bone. 2023. PMID: 36341949 Free article.

5

First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia.

Cheong HI, Yoo HW, Adachi M, Tanaka H, Fujiwara I, Hasegawa Y, Harada D, Sugimoto M, Okada Y, Kato M, Shimazaki R, Ozono K, Seino Y. Cheong HI, et al. JBMR Plus. 2018 Sep 14;3(2):e10074. doi: 10.1002/jbm4.10074. eCollection 2019 Feb. JBMR Plus. 2018. PMID: 30828689 Free PMC article.

6

Burosumab treatment for fibrous dysplasia.

Gladding A, Szymczuk V, Auble BA, Boyce AM. Gladding A, et al. Bone. 2021 Sep;150:116004. doi: 10.1016/j.bone.2021.116004. Epub 2021 May 11. Bone. 2021. PMID: 33984553 Free PMC article.

7

A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.

Huynh C, Gillis A, Fazendin J, Abdullatif H. Huynh C, et al. Bone Rep. 2022 Jul 20;17:101605. doi: 10.1016/j.bonr.2022.101605. eCollection 2022 Dec. Bone Rep. 2022. PMID: 35899095 Free PMC article.

8

Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.

Jurca CM, Iuhas O, Kozma K, Petchesi CD, Zaha DC, Bembea M, Jurca S, Paul C, Jurca AD. Jurca CM, et al. Genes (Basel). 2022 Aug 4;13(8):1392. doi: 10.3390/genes13081392. Genes (Basel). 2022. PMID: 36011303 Free PMC article. Review.

9

The effect of burosumab on intact and C-terminal FGF23 measurements.

Ashrafzadeh-Kian SL, Ito N, Srivastava T, Garg U, Kato H, Algeciras-Schimnich A, Bornhorst JA. Ashrafzadeh-Kian SL, et al. Clin Endocrinol (Oxf). 2023 Aug;99(2):152-157. doi: 10.1111/cen.14832. Epub 2022 Oct 31. Clin Endocrinol (Oxf). 2023. PMID: 36263608

10

Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.

Toi N, Imanishi Y, Nagata Y, Kurajoh M, Morioka T, Shoji T, Shinto Y, Emoto M. Toi N, et al. Endocr J. 2023 Apr 28;70(4):419-426. doi: 10.1507/endocrj.EJ22-0520. Epub 2022 Dec 28. Endocr J. 2023. PMID: 36575021 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year